Overview

Observational Study on the Use of NovoSeven® for Haemostatic Treatment of Bleeding Episodes in Patients With Acquired Haemophilia

Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
This study is conducted in Europe. The aim of this prospective, observational study are to describe the different clinical practice and detailed haemostatic management of activated recombinant human factor VII (NovoSeven®) in patients with acquired haemophilia in France. The secondary aim is to assess the primary haemostasis disorder associated with the coagulation disorders, if available.
Details
Lead Sponsor:
Novo Nordisk A/S
Treatments:
Hemostatics